Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast...

Area of Science:

• Oncology
• Pharmacology

Background:

• Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are standard treatment for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer (ABC/MBC).
• Limited real-world data exist on the long-term use and outcomes of CDK4/6i in Canadian patients with HR+/HER2- ABC/MBC.

Purpose of the Study:

• To evaluate the real-world treatment patterns and clinical outcomes of patients with HR+/HER2- ABC/MBC receiving CDK4/6i plus endocrine therapy (ET) in Canada.
• To assess the effectiveness of CDK4/6i + ET in the first-line (1L) setting using real-world data.

Main Methods:

• Artificial intelligence (AI) was used to extract real-world data from Sinai Health in Toronto, Canada, between January 1, 2016, and July 1, 2021.
• The study included 48 patients diagnosed with HR+/HER2- ABC/MBC who received CDK4/6i + ET.
• Treatment patterns, time to next treatment, time to chemotherapy, and overall survival were analyzed.

Main Results:

• Of 48 patients, 38 received CDK4/6i + ET in 1L, with 89.5% receiving palbociclib + ET.
• In second-line (2L), 57.1% of patients received CDK4/6i + ET, with abemaciclib being common.
• For 1L CDK4/6i + ET, the median time to next treatment was 42.3 months, and the two-year overall survival was 97.4%.

Conclusions:

• AI-extracted real-world data demonstrate the effectiveness of CDK4/6i + ET in the Canadian population with HR+/HER2- ABC/MBC.
• Palbociclib was the predominant CDK4/6i used in the first-line setting.
• The findings support the use of CDK4/6i + ET in real-world clinical practice for HR+/HER2- ABC/MBC.